Arcus Biosciences Inc (RCUS) Stock Price, Quote & News

Company Profile

Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's development product portfolio includes Casdatifan, a HIF-2a inhibitor for the treatment of kidney cancer; Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial for lung and gastrointestinal cancers; and Zimberelimab, an anti-PD-1 antibody. It also develops Quemliclustat, a small molecule inhibitor that targets the CD7...

Industry: Biotechnology

Sector: Healthcare

Phone: 510 694 6200

Website: arcusbio.com

Address:

3928 Point Eden Way, Hayward, United States

stcks Jun. 5 at 7:11 AM

$RCUS KOL Dr. Jingzhong Zhang (Moffitt GU Oncologist, manages ~90 RCC pts/year) on casdatifan from recent expert call: “Published data claim this is probably better than B, more effective and less toxic.” ORR ~45% vs ~23% and calls the Phase 3 design (head-to-head vs cabozantinib) “the better design” vs LITESPARK-011. Sees clear “appetite for using the casdatifan” if it delivers similar efficacy with better tolerability. Also notes adjuvant upside for more potent HIF-2α agents. Context on B + lenvatinib PFS benefit but curves separate late (~6 months). OS trending but not yet stat sig+heavy censoring at 18 months. Real-world safety concerns (anemia, hypoxia even without anemia, dose reductions) make the high-dose combo challenging, especially for elderly patients. ~60% of his 2L patients on cabo monotherapy. Combo approval could shift that share lower initially. Long-term bullish for RCUS if casdatifan differentiates on efficacy/toxicity. catalysts: P3 readouts & ASCO/ESMO updates.

0 · Reply

shukra_123 Jun. 3 at 2:49 PM

$RCUS https://investors.arcusbio.com/investors-and-media/press-releases/press-release-details/2026/Arcus-Biosciences-Announces-Clinical-Trial-Collaboration-and-Supply-Agreement-to-Evaluate-Casdatifan-in-Combination-with-PDL1VEGFA-Bispecific-Immunomodulator-to-Treat-Kidney-Cancer/default.aspx

0 · Reply

Doozio May. 30 at 3:03 PM

Chop chop huckleberries XBI gave da sign to cause a $RCUS again ONTO 🐒🍌🧠⏰♾️

1 · Reply

SuperGreenToday May. 19 at 8:59 AM

$RCUS Share Price: $23.40 Contract Selected: Dec 18, 2026 $20 Calls Buy Zone: $5.77 – $7.13 Target Zone: $9.43 – $11.53 Potential Upside: 54% ROI Time to Expiration: 212 Days | Updates via https://fxcapta.com/stockinfo/

0 · Reply

ACES_ May. 6 at 12:44 AM

$RCUS Focused management is a good thing. Cash is a good thing.

0 · Reply

Theobviouschoice May. 5 at 8:43 PM

$RCUS Nonsense 2 shares drop the sp 😠

0 · Reply

StocktwitsEarnings May. 5 at 8:14 PM

$RCUS Q1 '26 Earnings Results & Recap • Reported GAAP EPS of -$1.02 up 10.53% YoY • Reported revenue of $17M down -39.29% YoY • Arcus Biosciences believes its $876M in cash, cash equivalents, and marketable securities as of March 31, 2026, will fund planned operations until at least the second half of 2028.

0 · Reply

bryantboy99 May. 5 at 10:30 AM

$RCUS https://investors.arcusbio.com/investors-and-media/press-releases/press-release-details/2026/Arcus-Biosciences-to-Host-Conference-Call-to-Discuss-First-Quarter-2026-Financial-Results-and-Pipeline-Updates/default.aspx

0 · Reply

VAK7 May. 5 at 3:36 AM

$HOOD $KRYS $NBIS $RCUS $TGTX That was a very nice summary. And picks. And set me up for 75% 1 yeah performance since 5/4/25. TGTX and HOOD are lagging from this cohort of 5. But not for long. Imho TGTX will be over $45 this year; and HOOD will be in triple digits, no doubt about it. I could have done better, but, to my defense, MW should have sold TGTX before summer 2025; I told myself that if he does not do that, or buy out EU rights, i will reduce my TGTX position before 2 year term to buyback EU rights lapses. And I did not. Price you pay for your own indecisiveness.

0 · Reply

bryantboy99 May. 1 at 3:18 PM

$AUPH Come on Kevin, we need to get back on track and join my other bio's going to the moon $ETON and $RCUS while I patiently wait for $CTMX to catch up.

0 · Reply

Arcus Biosciences Transcript: AGM 2026

Jun 9, 2026, 4:35 PM EDT - 10 days ago

Arcus Biosciences Announces New Employment Inducement Grants

Jun 9, 2026, 10:40 AM EDT - 10 days ago

Arcus Biosciences Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026

Jun 9, 2026, 10:40 AM EDT - 10 days ago

Arcus Biosciences Slides: FY 2026

2026-06-04T10:43:24.000Z - 15 days ago

Arcus Biosciences initiated with an Outperform at LifeSci Capital

2026-06-03T13:40:17.000Z - 16 days ago

Arcus enters clinical trial collaboration, supply agreement with Bristol Myers

BMY

Jun 3, 2026, 8:00 AM EDT - 16 days ago

Arcus Biosciences Announces Clinical Trial Collaboration and Supply Agreement to Evaluate Casdatifan in Combination with PD‑L1/VEGF‑A Bispecific Immunomodulator to Treat Kidney Cancer

BMY

May 26, 2026, 4:05 PM EDT - 24 days ago

Arcus Biosciences to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference

2026-05-18T10:36:43.000Z - 4 weeks ago

Arcus Biosciences assumed with a Buy at Truist

2026-05-11T15:55:52.000Z - 5 weeks ago

Arcus Biosciences price target raised to $22 from $20 at Morgan Stanley

May 5, 2026, 4:30 PM EDT - 6 weeks ago

Arcus Biosciences Earnings Call Transcript: Q1 2026

May 5, 2026, 4:30 PM EDT - 6 weeks ago

Arcus Biosciences Slides: Q1 2026

May 5, 2026, 4:30 PM EDT - 6 weeks ago

Arcus Biosciences Earnings release: Q1 2026

May 5, 2026, 4:30 PM EDT - 6 weeks ago

Arcus Biosciences Quarterly report: Q1 2026

May 5, 2026, 4:05 PM EDT - 6 weeks ago

Arcus Biosciences Reports First-Quarter 2026 Financial Results and Provides a Pipeline Update

2026-04-22T15:01:23.000Z - 2 months ago

Arcus Biosciences rises 12.2%

Apr 21, 2026, 4:05 PM EDT - 2 months ago

Arcus Biosciences to Host Conference Call to Discuss First-Quarter 2026 Financial Results and Pipeline Updates

2026-04-21T16:16:40.000Z - 2 months ago

Merck setback has positives and negatives for Arcus Biosciences, says BofA

MRK

2026-04-21T16:11:24.000Z - 2 months ago

Merck study miss not a read for Arcus, says H.C. Wainwright

MRK

Apr 21, 2026, 8:00 AM EDT - 2 months ago

Arcus Biosciences Proxy statement: Proxy filing

Apr 21, 2026, 8:00 AM EDT - 2 months ago

Arcus Biosciences Proxy statement: Proxy filing

2026-04-20T19:05:48.000Z - 2 months ago

Arcus Biosciences discontinues Star-121 study with Gilead due to futility

GILD

2026-04-20T18:55:13.000Z - 2 months ago

Arcus Biosciences price target lowered to $47 from $49 at Leerink

GILD

2026-04-02T13:12:42.000Z - 2 months ago

Wedbush raises Arcus Biosciences price target to $41, adds to Best Ideas List

Mar 9, 2026, 11:20 AM EDT - 3 months ago

Arcus Biosciences Transcript: Leerink Global Healthcare Conference 2026

2026-03-05T11:38:20.000Z - 3 months ago

Arcus Biosciences price target raised to $45 from $44 at Citi

2026-03-02T11:10:31.000Z - 3 months ago

Arcus Biosciences price target raised to $49 from $36 at Leerink

Feb 26, 2026, 4:05 PM EST - 4 months ago

Arcus Biosciences to Participate in Two Upcoming Investor Conferences

2026-02-25T21:54:43.000Z - 4 months ago

Arcus Biosciences reports Q4 EPS (89c), consensus ($1.08)

2026-02-25T21:41:45.000Z - 4 months ago

Arcus Biosciences files automatic mixed securities shelf

Feb 25, 2026, 4:30 PM EST - 4 months ago

Arcus Biosciences Earnings Call Transcript: Q4 2025

Feb 25, 2026, 4:30 PM EST - 4 months ago

Arcus Biosciences Annual report: Q4 2025

Feb 25, 2026, 4:30 PM EST - 4 months ago

Arcus Biosciences Earnings release: Q4 2025

Feb 25, 2026, 4:30 PM EST - 4 months ago

Arcus Biosciences Slides: Q4 2025

Feb 25, 2026, 4:05 PM EST - 4 months ago

Arcus Biosciences Reports Fourth-Quarter and Full-Year 2025 Financial Results and Provides a Pipeline Update

2026-02-23T22:10:16.000Z - 4 months ago

Arcus Biosciences’ casdatifan shows increased survival in kidney cancer

Feb 23, 2026, 5:00 PM EST - 4 months ago

Arcus Presents New Data for its HIF-2a Inhibitor Casdatifan, Which Showed Progression-Free Survival Beyond One Year in Late-Line Kidney Cancer

2026-02-12T10:20:13.000Z - 4 months ago

Arcus Biosciences downgraded to Equal Weight from Overweight at Wells Fargo

EXEL

Feb 11, 2026, 4:05 PM EST - 4 months ago

Arcus Biosciences to Host Conference Call to Discuss Fourth-Quarter and Full-Year 2025 Financial Results and Pipeline Updates

Jan 14, 2026, 6:00 PM EST - 5 months ago

Arcus Biosciences Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 14, 2026, 6:00 PM EST - 5 months ago

Arcus Biosciences Slides: 44th Annual J.P. Morgan Healthcare Conference

2026-01-12T21:30:13.000Z - 5 months ago

Arcus Biosciences upgraded to Buy from Neutral at Goldman Sachs

2026-01-08T10:05:26.000Z - 5 months ago

Arcus Biosciences downgraded to Equal Weight from Overweight at Morgan Stanley

Jan 7, 2026, 4:05 PM EST - 5 months ago

Arcus Outlines 2026 Plans for Casdatifan, its Potential Best-in-Class HIF-2a Inhibitor, and its Inflammation Programs

Dec 18, 2025, 4:05 PM EST - 6 months ago

Arcus Biosciences to Participate in the 44th Annual J.P. Morgan Healthcare Conference

Dec 12, 2025, 8:30 AM EST - 6 months ago

Arcus Provides Update on Phase 3 STAR-221 Study and Concentrates Its R&D Investment on Casdatifan and Emerging Inflammation and Immunology Portfolio

Dec 12, 2025, 7:00 AM EST - 6 months ago

Arcus Biosciences Slides: Investor presentation

Dec 3, 2025, 10:30 AM EST - 7 months ago

Arcus Biosciences Transcript: Citi Annual Global Healthcare Conference 2025

Dec 2, 2025, 4:40 PM EST - 7 months ago

Arcus Biosciences Transcript: Evercore ISI 8th Annual HealthCONx Conference

Oct 30, 2025, 11:35 PM EDT - 8 months ago

Arcus Biosciences Announces Pricing of $250 Million Public Offering of Common Stock

Oct 30, 2025, 4:01 PM EDT - 8 months ago

Arcus Biosciences Announces Commencement of Public Offering of Common Stock

Oct 28, 2025, 4:05 PM EDT - 8 months ago

Arcus Biosciences Reports Third-Quarter 2025 Financial Results and Provides a Pipeline Update

Oct 28, 2025, 4:00 PM EDT - 8 months ago

Arcus Biosciences Quarterly report: Q3 2025

Oct 28, 2025, 4:00 PM EDT - 8 months ago

Arcus Biosciences Earnings release: Q3 2025

Oct 19, 2025, 7:00 PM EDT - 8 months ago

Taiho Pharmaceutical Exercises Option for an Exclusive License to Casdatifan in Japan and Certain Territories in Asia

Oct 12, 2025, 6:05 PM EDT - 8 months ago

Anti-TIGIT Domvanalimab Plus Anti-PD-1 Zimberelimab and Chemotherapy Showed 26.7 Months of Median Overall Survival as First-Line Treatment of Unresectable or Advanced Gastroesophageal Adenocarcinomas in the Phase 2 EDGE-Gastric Study

Oct 6, 2025, 10:00 AM EDT - 9 months ago

Arcus Biosciences Transcript: R&D Day 2025

Oct 6, 2025, 10:00 AM EDT - 9 months ago

Arcus Biosciences Slides: FY 2025

Oct 6, 2025, 8:00 AM EDT - 9 months ago

Arcus Biosciences Presents New Data for its HIF-2a Inhibitor Casdatifan and Discloses First Inflammation Programs at Investor Event

Sep 10, 2025, 8:30 AM EDT - 10 months ago

Arcus Biosciences Transcript: Morgan Stanley 23rd Annual Global Healthcare Conference

Sep 9, 2025, 8:00 AM EDT - 10 months ago

Arcus Biosciences Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Sep 3, 2025, 11:15 AM EDT - 10 months ago

Arcus Biosciences Transcript: Citi's Biopharma Back to School Conference

Sep 2, 2025, 4:05 PM EDT - 10 months ago

Arcus Biosciences to Host Investor Event to Highlight its Late-Stage Casdatifan Program and Next Wave of Programs Focused on Inflammation

Aug 20, 2025, 4:05 PM EDT - 10 months ago

Arcus Biosciences to Participate in Three Upcoming Investor Conferences

Aug 6, 2025, 4:05 PM EDT - 11 months ago

Arcus Biosciences Reports Second-Quarter 2025 Financial Results and Provides a Pipeline Update

Aug 6, 2025, 4:05 PM EDT - 11 months ago

Arcus Biosciences Quarterly report: Q2 2025

Aug 6, 2025, 4:05 PM EDT - 11 months ago

Arcus Biosciences Earnings release: Q2 2025

Aug 6, 2025, 4:05 PM EDT - 11 months ago

Arcus Biosciences Slides: Q2 2025

Jul 10, 2025, 8:30 AM EDT - 1 year ago

Arcus Biosciences' Quemliclustat Receives Orphan Drug Designation for Pancreatic Cancer

Jun 2, 2025, 8:00 AM EDT - 1 year ago

Arcus Biosciences Transcript: Study Update

Jun 2, 2025, 8:00 AM EDT - 1 year ago

Arcus Biosciences Press release: Study Update

Jun 2, 2025, 8:00 AM EDT - 1 year ago

Arcus Biosciences Slides: Study Update

Jun 1, 2025, 10:45 AM EDT - 1 year ago

Initial Data from the ARC-20 Study of Casdatifan Plus Cabozantinib Showed Nearly Half of Patients with Metastatic Kidney Cancer Had a Confirmed Response

May 6, 2025, 4:30 PM EDT - 1 year ago

Arcus Biosciences Earnings Call Transcript: Q1 2025

May 6, 2025, 4:30 PM EDT - 1 year ago

Arcus Biosciences Quarterly report: Q1 2025

May 6, 2025, 4:30 PM EDT - 1 year ago

Arcus Biosciences Earnings release: Q1 2025

May 6, 2025, 4:30 PM EDT - 1 year ago

Arcus Biosciences Slides: Q1 2025

May 6, 2025, 4:05 PM EDT - 1 year ago

Arcus Biosciences Reports First-Quarter 2025 Financial Results and Provides a Pipeline Update

Apr 23, 2025, 4:05 PM EDT - 1 year ago

Arcus Biosciences to Present First Combination Data for HIF-2a Inhibitor Casdatifan Plus Cabozantinib in an Oral Presentation at the 2025 ASCO Annual Meeting

Apr 22, 2025, 4:05 PM EDT - 1 year ago

Arcus Biosciences to Host Conference Call to Discuss First-Quarter 2025 Financial Results and Pipeline Update

Apr 22, 2025, 8:00 AM EDT - 1 year ago

Arcus Biosciences Proxy statement: Proxy Filing

Apr 22, 2025, 8:00 AM EDT - 1 year ago

Arcus Biosciences Proxy statement: Proxy Filing

Mar 13, 2025, 8:00 AM EDT - 1 year ago

Arcus Biosciences Transcript: Barclays 27th Annual Global Healthcare Conference

Mar 12, 2025, 8:00 AM EDT - 1 year ago

Arcus Biosciences Transcript: Leerink’s Global Healthcare Conference 2025

Feb 25, 2025, 4:05 PM EST - 1 year ago

Arcus Biosciences Reports Fourth-Quarter and Full-Year 2024 Financial Results and Provides a Pipeline Update

Feb 25, 2025, 4:05 PM EST - 1 year ago

Arcus Biosciences Annual report: Q4 2024

Feb 25, 2025, 4:05 PM EST - 1 year ago

Arcus Biosciences Earnings release: Q4 2024

Feb 25, 2025, 4:05 PM EST - 1 year ago

Arcus Biosciences Slides: Q4 2024

Feb 18, 2025, 8:00 AM EST - 1 year ago

Arcus Biosciences Transcript: Status Update

Feb 18, 2025, 8:00 AM EST - 1 year ago

Arcus Biosciences Press release: Status Update

Feb 18, 2025, 8:00 AM EST - 1 year ago

Arcus Biosciences Slides: Status Update

Feb 18, 2025, 6:57 AM EST - 1 year ago

Arcus Biosciences Retains Rights to Casdatifan, a Potential Best-in-Class HIF-2a Inhibitor, and Announces Pricing of $150 Million Common Stock Offering

Feb 18, 2025, 6:52 AM EST - 1 year ago

Arcus Biosciences, Inc. Announces Underwritten Offering of Common Stock

Feb 15, 2025, 3:45 PM EST - 1 year ago

New Data Demonstrated Best-in-Class Potential for Casdatifan, a HIF-2a Inhibitor, in Patients with Metastatic Kidney Cancer

Feb 10, 2025, 5:00 PM EST - 1 year ago

Arcus Biosciences to Present New Data from Casdatifan, a HIF-2a Inhibitor, in an Oral Presentation at the 2025 ASCO GU Symposium

Jan 21, 2025, 4:05 PM EST - 1 year ago

Arcus Biosciences Appoints Richard Markus, M.D., Ph.D. as Chief Medical Officer

Jan 14, 2025, 6:45 PM EST - 1 year ago

Arcus Biosciences Transcript: 43rd Annual J.P. Morgan Healthcare Conference 2025

Jan 14, 2025, 6:45 PM EST - 1 year ago

Arcus Biosciences Slides: FY 2025

Dec 19, 2024, 4:05 PM EST - 1 year ago

Arcus Biosciences to Participate in the 43rd Annual J.P. Morgan Healthcare Conference

Dec 3, 2024, 7:55 AM EST - 1 year ago

Arcus Biosciences Transcript: 7th Annual Evercore ISI HealthCONx Conference

Nov 6, 2024, 5:00 PM EST - 1 year ago

Arcus Biosciences Earnings Call Transcript: Q3 2024

Nov 6, 2024, 5:00 PM EST - 1 year ago

Arcus Biosciences Quarterly report: Q3 2024

Nov 6, 2024, 5:00 PM EST - 1 year ago

Arcus Biosciences Earnings release: Q3 2024

Nov 6, 2024, 5:00 PM EST - 1 year ago

Arcus Biosciences Slides: Q3 2024

Nov 6, 2024, 4:22 PM EST - 1 year ago

Arcus Biosciences Reports Third-Quarter 2024 Financial Results and Provides a Pipeline Update

Nov 5, 2024, 9:00 AM EST - 1 year ago

Arcus Biosciences Announces that Domvanalimab Plus Zimberelimab Improved Overall Survival in ARC-10, a Randomized Study in Patients with PD-L1-High Non-Small Cell Lung Cancer

Oct 30, 2024, 9:00 AM EDT - 1 year ago

Arcus Biosciences to Present New Data for Anti-TIGIT Domvanalimab Plus Zimberelimab at the Society for Immunotherapy of Cancer Annual Meeting

Oct 24, 2024, 8:00 AM EDT - 1 year ago

Arcus Biosciences Transcript: Study Update

Oct 24, 2024, 8:00 AM EDT - 1 year ago

Arcus Biosciences Press release: Study Update

Oct 24, 2024, 8:00 AM EDT - 1 year ago

Arcus Biosciences Slides: Study Update

Oct 24, 2024, 7:30 AM EDT - 1 year ago

First Clinical Data for Arcus Biosciences' HIF-2a Inhibitor, Casdatifan, Showed Promising Clinical Activity and Tumor Shrinkage in Patients with Metastatic Kidney Cancer

Oct 22, 2024, 4:05 PM EDT - 1 year ago

Arcus Biosciences to Host Conference Call to Discuss Third-Quarter 2024 Financial Results and Pipeline Update

Oct 9, 2024, 8:00 AM EDT - 1 year ago

Arcus Biosciences to Present First Clinical Data from ARC-20 Study at the 2024 EORTC-NCI-AACR Symposium

Oct 2, 2024, 4:05 PM EDT - 1 year ago

Arcus Biosciences Announces Clinical Trial Collaboration Agreement to Evaluate Casdatifan in Combination with Volrustomig in Renal Cell Carcinoma

AZN

Sep 19, 2024, 10:55 AM EDT - 1 year ago

Arcus Biosciences Transcript: 2024 Cantor Fitzgerald Global Healthcare Conference

Sep 19, 2024, 10:55 AM EDT - 1 year ago

Arcus Biosciences Transcript: 2024 Cantor Global Healthcare Conference

Sep 4, 2024, 4:50 PM EDT - 1 year ago

Arcus Biosciences Transcript: Morgan Stanley 22nd Annual Global Healthcare Conference

Aug 27, 2024, 4:05 PM EDT - 1 year ago

Arcus Biosciences Secures Up to $250 Million Term Loan Facility from Hercules Capital

HTGC

Aug 8, 2024, 5:00 PM EDT - 2 years ago

Arcus Biosciences Earnings Call Transcript: Q2 2024

Aug 8, 2024, 5:00 PM EDT - 2 years ago

Arcus Biosciences Quarterly report: Q2 2024

Aug 8, 2024, 5:00 PM EDT - 2 years ago

Arcus Biosciences Earnings release: Q2 2024

Aug 8, 2024, 5:00 PM EDT - 2 years ago

Arcus Biosciences Slides: Q2 2024

Aug 8, 2024, 4:05 PM EDT - 2 years ago

Arcus Biosciences Reports Second-Quarter 2024 Financial Results and Provides a Pipeline Update

Jul 25, 2024, 4:05 PM EDT - 2 years ago

Arcus Biosciences to Host Conference Call to Discuss Second-Quarter 2024 Financial Results and Pipeline Update

Jul 8, 2024, 6:00 PM EDT - 2 years ago

Taiho Pharmaceutical Exercises Option for an Exclusive License to Quemliclustat in Japan and Certain Territories in Asia

Jun 12, 2024, 10:00 AM EDT - 2 years ago

Arcus Biosciences Transcript: Goldman Sachs 45th Annual Global Healthcare Conference

Jun 10, 2024, 8:30 AM EDT - 2 years ago

Arcus Biosciences Completes Patient Enrollment in Phase 3 Trial Evaluating a Domvanalimab-Containing Regimen in First-Line Metastatic Upper GI Cancers

Jun 6, 2024, 4:05 PM EDT - 2 years ago

Arcus Biosciences to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference

Jun 2, 2024, 8:00 AM EDT - 2 years ago

Gilead and Arcus Announce Etrumadenant Plus Zimberelimab Regimen Significantly Reduced the Risk of Death in Third-line Metastatic Colorectal Cancer

GILD

Jun 1, 2024, 8:00 AM EDT - 2 years ago

Gilead and Arcus Announce Anti-TIGIT Domvanalimab Plus Zimberelimab and Chemotherapy Exceeded One Year of Median Progression-Free Survival as a First-Line Treatment for Upper GI Cancers

GILD

May 16, 2024, 1:00 PM EDT - 2 years ago

Arcus Biosciences Transcript: BofA Securities 2024 Health Care Conference

May 8, 2024, 4:30 PM EDT - 2 years ago

Arcus Biosciences Earnings Call Transcript: Q1 2024

May 8, 2024, 4:30 PM EDT - 2 years ago

Arcus Biosciences Quarterly report: Q1 2024

May 8, 2024, 4:30 PM EDT - 2 years ago

Arcus Biosciences Earnings release: Q1 2024

May 8, 2024, 4:30 PM EDT - 2 years ago

Arcus Biosciences Slides: Q1 2024

May 8, 2024, 4:02 PM EDT - 2 years ago

Arcus Biosciences Reports First-Quarter 2024 Financial Results and Provides a Pipeline Update

May 2, 2024, 4:05 PM EDT - 2 years ago

Arcus Biosciences to Participate in the Bank of America Healthcare Conference 2024

stcks Jun. 5 at 7:11 AM

0 · Reply

shukra_123 Jun. 3 at 2:49 PM

0 · Reply

Doozio May. 30 at 3:03 PM

Chop chop huckleberries XBI gave da sign to cause a $RCUS again ONTO 🐒🍌🧠⏰♾️

1 · Reply

SuperGreenToday May. 19 at 8:59 AM

0 · Reply

ACES_ May. 6 at 12:44 AM

$RCUS Focused management is a good thing. Cash is a good thing.

0 · Reply

Theobviouschoice May. 5 at 8:43 PM

$RCUS Nonsense 2 shares drop the sp 😠

0 · Reply

StocktwitsEarnings May. 5 at 8:14 PM

0 · Reply

bryantboy99 May. 5 at 10:30 AM

0 · Reply

VAK7 May. 5 at 3:36 AM

0 · Reply

bryantboy99 May. 1 at 3:18 PM

$AUPH Come on Kevin, we need to get back on track and join my other bio's going to the moon $ETON and $RCUS while I patiently wait for $CTMX to catch up.

0 · Reply

LiveCommander Apr. 22 at 11:04 PM

$RCUS nice breakout

0 · Reply

JazzyJ03 Apr. 22 at 3:19 PM

$RCUS

0 · Reply

bryantboy99 Apr. 22 at 3:08 PM

$AUPH Come on Tang, gonna need Auph to catch up to $RCUS if you don't mind.

0 · Reply

bryantboy99 Apr. 22 at 2:37 PM

$RCUS

0 · Reply

RunnerSignals Apr. 21 at 8:32 PM

market warriors $HRMY $RCUS $ANNA $BNTX $REI flipped red to green HRMY 5.8x vol and RCUS 3.3x show real accumulation, BNTX solid follow-through; REI ANNA lighter suggest mixed short covering

0 · Reply

stcks Apr. 21 at 8:08 PM

$RCUS Merck and Eisai’s Phase 3 LITESPARK-012 trial (also called MK-6482-012) tested two experimental triplet regimens in previously untreated patients with advanced ccRCC: • KEYTRUDA (pembrolizumab) + LENVIMA (lenvatinib) + WELIREG (belzutifan, Merck’s HIF-2α inhibitor) • Or a coformulation of KEYTRUDA + quavonlimab (an anti-CTLA-4) + LENVIMA Both arms failed to beat the control arm of KEYTRUDA + LENVIMA alone on the dual primary endpoints of progression-free survival (PFS) and overall survival (OS) at a pre-specified interim analysis. Safety was consistent with prior data, but the regimens did not show added benefit. • Broader implications: It reinforces that simply piling on more agents to the established KEYTRUDA + LENVIMA backbone doesn’t automatically improve outcomes in frontline RCC. This shifts focus back to other mechanisms, lines of therapy, and competitors in the HIF-2α space.

1 · Reply

stcks Apr. 21 at 8:00 PM

$RCUS Merck’s new kidney cancer combos failed in Phase 3, missing key goals.

0 · Reply

notreload_ai Apr. 21 at 7:40 PM

$MRK new kidney cancer combos failed in Phase 3, missing key goals; analysts see mixed impact for $RCUS and its drug. https://notreload.xyz/xy/merck-litespark-012-miss-boost-for-arcus/

0 · Reply

bryantboy99 Apr. 21 at 7:04 PM

$RCUS market must like this news and possible implications for RCUS. https://www.biopharmadive.com/news/merck-welireg-1l-renal-cell-carcinoma-study-results/818093/

0 · Reply

grandefappuccino Apr. 20 at 8:01 PM

$RCUS ooooof

0 · Reply

notreload_ai Apr. 20 at 7:53 PM

$RCUS stops a lung cancer trial early after poor outlook, ends a partner study, and gains more control as $GILD scales back the deal. https://notreload.xyz/xy/rcus-halts-star-121-phase-3-trial-gilead-update/

0 · Reply

Market Cap	3.06B
Revenue (ttm)	247.00M
Net Income (ttm)	-353.00M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-142.92%
Debt to Equity Ratio	0.19

Volume	2,309,000
Avg Vol	1,167,100
Day's Range	N/A - N/A
Shares Out	125.77M
Stochastic %K	82%
Beta	0.85
Analysts	Strong Sell
Price Target	$35.75